^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CRL4-CRBN E3 ubiquitin ligase modulator

    Related drugs:
    12d
    GOLSEEK-2: A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, Celgene | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • prednisone • bendamustine • golcadomide (CC-99282)
    18d
    A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    dexamethasone • Empliciti (elotuzumab) • iberdomide (CC-220)
    1m
    Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma (clinicaltrials.gov)
    P2, N=36, Recruiting, M.D. Anderson Cancer Center | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial primary completion date
    |
    Gazyva (obinutuzumab) • golcadomide (CC-99282)
    1m
    Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Hackensack Meridian Health | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    carfilzomib • dexamethasone • iberdomide (CC-220)
    1m
    Go-Pro-DLBCL: Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Seoul National University Hospital
    New P1/2 trial
    |
    Rituxan (rituximab) • golcadomide (CC-99282) • poseltinib (HM71224)
    3ms
    Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. (PubMed, Blood Cancer Discov)
    Golcadomide exhibited rapid, deep, and sustained degradation of transcription factors IKZF1 and IKZF3, surpassing the anti-tumor activity of the IMiD® agent lenalidomide in preclinical models. Pharmacological and CRISPR screening further revealed genes and pathways underlying golcadomide's antitumor efficacy. These findings supported golcadomide as a promising drug candidate for DLBCL, providing a strong rationale for future golcadomide-based regimens.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • IKZF3 (IKAROS Family Zinc Finger 3)
    |
    lenalidomide • golcadomide (CC-99282)
    3ms
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial primary completion date: May 2027 --> Mar 2026
    Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    4ms
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    4ms
    Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (clinicaltrials.gov)
    P2, N=68, Recruiting, Emory University | Trial completion date: Oct 2025 --> Sep 2029 | Trial primary completion date: Sep 2025 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    iberdomide (CC-220)
    5ms
    An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden. (PubMed, Blood)
    The addition of anti-PD1 and pomalidomide reduced the T cell exhaustion that occurs in response to TCE in high tumor burden settings. This was accompanied by more favorable T cell profiling, with limited expansion of regulatory T cells and exhaustion. In total, administering TCE following dexamethasone and iberdomide treatments provided deeper and more durable responses with reduced risk of CRS.
    Journal
    |
    IKZF1 (IKAROS Family Zinc Finger 1)
    |
    dexamethasone • pomalidomide • iberdomide (CC-220)
    5ms
    TOP-FLOR: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive • LDH elevation
    |
    Opdivo (nivolumab) • Rituxan (rituximab) • golcadomide (CC-99282)
    5ms
    FIL_RICCO: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (clinicaltrials.gov)
    P2, N=47, Recruiting, Fondazione Italiana Linfomi - ETS | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • golcadomide (CC-99282)